Advanced Oncotherapy – Exercise of Warrants and Issue of Shares

Exercise of Warrants and Issue of Shares.

Issue of Shares

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 600,000 new ordinary shares of 1p in the Company at a subscription price of 8 pence per Ordinary Share to Dr Enrico Vanni, a non-executive director, in lieu of his non-executive director fee and fees in connection with his providing operational management support to the Company’s ADAM subsidiary.

Following this transaction, Dr Vanni now holds 13,050,000 Ordinary Shares representing 0.97% of the issued share capital of the Company.

Exercise of Warrants and Issue of Shares

The company further announces that it has today issued 16,400 new ordinary shares of 1p in the Company at a price of 6 pence per Further Share pursuant to the exercise of warrants.

Admission

Application has been made for the 600,000 New Ordinary Shares and the 16,400 Further Shares to be admitted to trading on AIM and it is expected that Admission will occur on 21 July 2015. The Shares will rank pari passu in all respect with the existing Shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,377,039,026 Shares, with voting rights. The Company does not hold any Shares in treasury. Therefore the total number of Shares in the Company with voting rights will be 1,377,039,026. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact: